title: Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
authors.forename: F T
authors.initials: FT
authors.lastname: Awan
authors.forename: S
authors.initials: S
authors.lastname: Osman
authors.forename: S T
authors.initials: ST
authors.lastname: Kochuparambil
authors.forename: L
authors.initials: L
authors.lastname: Gibson
authors.forename: S C
authors.initials: SC
authors.lastname: Remick
authors.forename: J
authors.initials: J
authors.lastname: Abraham
authors.forename: M
authors.initials: M
authors.lastname: Craig
authors.forename: A
authors.initials: A
authors.lastname: Jillella
authors.forename: M
authors.initials: M
authors.lastname: Hamadani
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011719:Pyrazines / Q000008:administration & dosage*; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide